Dr. Deborah Fuller is a Professor in the Department of Microbiology at the University of Washington School of Medicine and Chief of the Infectious Diseases and Translational Medicine Division at the Washington National Primate Research Center. Prior to her academic career, Dr. Fuller worked in biotechnology developing vaccines against HIV, HBV and emerging infectious diseases. In 2004, she transitioned to academia where she is leading a team developing nucleic acid vaccine platform technologies and investigating immune mechanisms of protection and pathogenesis of viral infections. She recently developed a vaccine for COVID-19 that is scheduled to enter human clinical trials in Fall 2020. Dr. Fuller is a co-founder of a biotechnology company, Orlance, Inc (www.orlance.com) that aims to advance nucleic acid vaccines to clinical testing. She is currently a member of the National Institute of Allergy and Infectious Diseases (NIAID) Vaccines for Microbial Diseases (VMD) study section and serving on the leadership team for the Nonhuman Primate COVID Vaccines and Therapeutics Evaluation Network to accelerate the development of promising COVID-19 vaccines and antivirals. She has led translation of two vaccines from bench to clinical trials, authored 80 manuscripts and is a co-inventor on over a dozen patents for vaccines and antivirals.